Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS (NOVN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest Tweets
08:15a$ROG - Roche Holding Ltd. #ROG Given a CHF 295 Price Target by Jefferies Grou.. 
07:15a#TourofGuangxi Correction: it seems it's @nicholasroche in the breakaway, not..
1
03:14aRoche may be asking too much of its next generation of medicines  
03:02aWall Street seems to expect too much from Roche's new drugs
15
01:28aRoche's newer drugs have some heavy lifting to do
1
12:18aRoche feeling first effects of biosimilar Rituxan: Biopharma Dive
1
10/19Wall Street seems to expect too much from Roche's new drugs
5
10/19Wall Street may be expecting too much from Roche's new drugs  
10/19Wall Street seems to expect too much from Roche's new drugs
4
10/19Roche Holding given CHF 260 PT by UBS AG. neutral rating.  
10/19Move over, Novartis: Kite and Gilead break into CAR-T market with early axi-c.. 
10/19Novartis to shut U.S. generics plant, cut 450 jobs | Pharma Magazine  
10/19Roche Holding ADR reports Q3 results  
10/19$RHHBY: Roche Hldg reports Q3 sales and reaffirms FY17 sales outlook  
10/19Roche Q3 top line up 5%, guidance confirmed  
10/19Novartis to shut U.S. generics plant, cut 450 jobs
40
10/19Novartis to phase out 450 jobs amid plant shutdown  
10/19Novartis to shut U.S. generics plant, cut 450 jobs
10
10/19Novartis to shut U.S. generics plant, cut 450 jobs
5
10/19Novartis to shut US generics plant, cut 450 jobs
2
10/19[CNA] Novartis to shut US generics plant, cut 450 jobs  
10/19Novartis to shut U.S. generics plant, cut 450 jobs -  
10/19Novartis to shut U.S. generics plant, cut 450 jobs  
10/19Novartis to shut U.S. generics plant, cut 450 jobs
7
10/19Novartis to shut U.S. generics plant, cut 450 jobs  
10/19New MS drug #Ocrevus lifts #Roche as #biosimilars bite, with #Rituxan/MabTher..
3
10/19Novartis to shut U.S. generics plant, cut 450 jobs  
10/19UPDATE 2-New MS drug lifts Roche as biosimilars bite in Europe  
10/19Swiss biotech group Roche sees 5 pct rise in 9-month sales - Washington Post .. 
10/19Same old, same old at #Roche. Since the Novo Nordisk romp my current fav Eur.. 
10/19U.S. #FDA approves #Gilead #CAR-T #cancer gene therapy; price set at $373,000..
2
10/19UPDATE 1-Roche Q3 sales beat forecasts as Ocrevus shines  
10/19Roche third-quarter sales beat forecasts as Ocrevus shines
2
10/19$NOVN, $The - Novartis AG #NOVN Given a CHF 80 Price Target by Goldman Sachs .. 
10/19Roche Q3 sales beat forecasts as Ocrevus shines  
10/19US helps offset lower European sales for Roche  
10/19US helps offset lower European sales for Roche  
10/19US helps offset lower European sales for Roche  
10/19US helps offset lower European sales for Roche
6
10/19#UCBerkeley deal showcases #biotech @Novartis' new focus on #academic tie-ups.. 
10/18$NVS: Novartis AG announces publication of l/t study results of Promacta in t..
1
10/18Roche Holding Ltd. $RHHBY Downgraded by Citigroup Inc. to Neutral  
10/18Novartis' eltrombopag shows long-term treatment benefit patients with low blo.. 
10/18Roche Holding downgraded by Citigroup Inc. to neutral.  
10/18$NVS: Novartis reports data for Revolade demonstrating 70% of patients mainta.. 
10/18I am certainly concerned about price caps: Shravan Subramanyam, MD of Roche D.. 
10/18Roche Holding given CHF 255 PT by Citigroup Inc.. neutral rating.  
10/18Novartis says ?revolade shows long-term disease control for chronic/persisten.. 
10/18Novartis says ?revolade shows long-term disease control for chronic/persisten.. 
10/18Roche Holding given CHF 325 PT by Goldman Sachs Group, Inc. (The). buy rating.. 
More tweets
Qtime:387
Financials ($)
Sales 2017 48 803 M
EBIT 2017 11 558 M
Net income 2017 7 295 M
Debt 2017 17 704 M
Yield 2017 3,30%
P/E ratio 2017 25,45
P/E ratio 2018 21,73
EV / Sales 2017 4,97x
EV / Sales 2018 4,75x
Capitalization 225 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,4 $
Spread / Average Target 1,2%
EPS Revisions
Managers
NameTitle
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS13.50%226 453
JOHNSON & JOHNSON22.11%377 585
ROCHE HOLDING LTD.5.55%215 760
PFIZER10.31%213 372
MERCK AND COMPANY7.88%173 214
AMGEN27.41%135 924